Novo Nordisk A/S vs Vanguard Tax Managed Fund FTSE Developed Markets ETF — how do they compare? Novo Nordisk A/S trades at $49.35 (market cap $220.53B), while Vanguard Tax Managed Fund FTSE Developed Markets ETF trades at $70.47. The key difference: Novo Nordisk A/S pays a 3.63% dividend while Vanguard Tax Managed Fund FTSE Developed Markets ETF pays none, and Vanguard Tax Managed Fund FTSE Developed Markets ETF is trading nearer its 52-week high, Novo Nordisk A/S nearer its low. Which is the better fit depends on your goals.
| NVO | VEA | |
|---|---|---|
Market Cap | $220.53B | — |
Sector | Health | — |
52-Week High | $71.70 | $72.39 |
52-Week Low | $35.29 | $56.02 |
Enterprise Value | $239.49B | — |
Dividend Yield | 3.63% | — |
Trailing returns across standard periods
Latest headlines on both assets
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →The fund employs an indexing investment approach designed to track the performance of the FTSE Developed All Cap ex US Index, a market-capitalization-weighted index that is made up of approximately 4022 common stocks of large-, mid-, and small-cap companies located in Canada and the major markets of Europe and the Pacific region. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VEA →